We are thrilled to share the announcement today that Digistain® are 1 of 4 FINALISTS for the 2024 Nature Spin-off Prize
Over 150 innovative technologies were diligently evaluated by a panel of scientists so we are very proud that our novel approach to breast cancer diagnostics has been recognised by this prestigious award panel.
Digistain was a finalist for the 2024 Nature Spin-off Prize.
Digistain has been nominated for the EIT Awards 2026 in the Venture Award category. The Venture Award recognises organisations combining strong commercial potential with meaningful
In September 2026 Sasha Becejac, Digistain’s CCO, was invited to speak at On Targeted Molecular Oncology 2026 in Ankara, Türkiye, sharing the latest developments around
In September 2026 Sarah Bond, our COO for the MENA region, took part in The Future Health Dialogue roundtable hosted at Hub71 in Abu Dhabi,
Supported by:
To stay updated about Digistain’s developments, enter your details opposite. We promise only to send you important news.